Volume 15, Number 6—June 2009
Research
Changes in Fluoroquinolone-Resistant Streptococcus pneumonia after 7-Valent Conjugate Vaccination, Spain
Figure

Figure. Serotype (A) and genotype (B) distributions of ciprofloxacin-resistant pneumococci isolated in Spain, 2002 and 2006. A total of 75 isolates from 2002 (black columns) and 98 from 2006 (white columns) were compared. Asterisks indicate significant differences (p<0.05) between the 2 years. PCV7, 7-valent conjugate pneumococcal vaccine. Baseline numbers in B indicate various genotypes. 1, Spain6B-ST90; 2, Spain9V-ST156; 3, Spain14-ST17; 4, Netherlands18C-ST113; 5, ST8819F; 6, Spain23F-ST81; 7, Netherlands3-ST180; 8, ST2603; 9, ST9710A; 10, ST6211A; 11, Sweden15A-ST63; 12, ST57016; 13, TS43322; 14, ST71733; 15, other.
Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.